No tags found

Companies

No companies found

Advanced Search

Newsfeed

Alerts

Saved Lists

Source: Jewish Business News

Cancer Therapeutics CRC : Australian Cancer Drug Licensed in $730 Million Deal

Read full article »

Cancer Therapeutics CRC 's Competitors | Cancer Therapeutics CRC 's News | Cancer Therapeutics CRC 's Financials

January 29, 2023

Medthority

Phase III STAND study of crizanlizumab shows no significant difference between doses for treating sickle cell disease pain crises.- Novartis

The preliminary results from the ongoing global phase III study STAND (NCT03814746) indicate no stati... See more »

January 28, 2023

centralcharts

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Fate Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline - FATE

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Fate Th... See more »

January 27, 2023

Seeking Alpha

Novartis sees no benefit of Adakveo for sickle cell ailment in phase 3 trial

January 27, 2023MarketScreener

Bristol Myers Gets CHMP Backing for Sotyktu, Reblozyl

(marketscreener.com) By Colin Kellaher Bristol Myers Squibb Co. on Friday said the European Medicines... See more »

January 28, 2023Medthority

CHMP recommends approval of Sotyktu in plaque psoriasis.- Bristol Myers Squibb

Bristol Myers Squibb announced that the Committee for Medicinal Products for Human Use (CHMP) of the ... See more »

January 28, 2023Medthority

Positive CHMP opinion for Reblozyl for adult patients with anemia-associated, non-transfusion dependent(NTD) beta thalassemia.- BMS

Bristol Myers Squibb announced the Committee for Medicinal Products for Human Use (CHMP) of the Europ... See more »

January 27, 2023Nasdaq

Could This Be Novartis' Next Blockbuster Medicine?

Last month, Novartis (NYSE: NVS) revealed encouraging results from a phase 3 clinical trial of the ra... See more »

January 28, 2023Post Online Media

Once-daily Sotyktu gets positive opinion as treatment for adults with moderate-to-severe plaque psoriasis

Bristol Myers Squibb announced that the Committee for Medicinal Products for Human Use (CHMP) of the ... See more »

January 27, 2023MedicalMarketing& Media

Bristol Myers Squibb to settle lawsuit with two employees fired for refusing COVID-19 vaccine

The employees sued the company after BMS allegedly rejected their bids for religious exemption from v... See more »

January 29, 2023

Medthority

Phase III STAND study of crizanlizumab shows no significant difference between doses for treating sickle cell disease pain crises.- Novartis

The preliminary results from the ongoing global phase III study STAND (NCT03814746) indicate no stati... See more »

January 28, 2023

centralcharts

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Fate Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline - FATE

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Fate Th... See more »

January 27, 2023

Seeking Alpha

Novartis sees no benefit of Adakveo for sickle cell ailment in phase 3 trial

January 27, 2023MarketScreener

Bristol Myers Gets CHMP Backing for Sotyktu, Reblozyl

(marketscreener.com) By Colin Kellaher Bristol Myers Squibb Co. on Friday said the European Medicines... See more »

January 28, 2023Medthority

CHMP recommends approval of Sotyktu in plaque psoriasis.- Bristol Myers Squibb

Bristol Myers Squibb announced that the Committee for Medicinal Products for Human Use (CHMP) of the ... See more »

January 28, 2023Medthority

Positive CHMP opinion for Reblozyl for adult patients with anemia-associated, non-transfusion dependent(NTD) beta thalassemia.- BMS

Bristol Myers Squibb announced the Committee for Medicinal Products for Human Use (CHMP) of the Europ... See more »

January 27, 2023Nasdaq

Followers on Owler

Est. Annual Revenue

$100K-5.0M

Agree?

Est. Employees

1-25

Agree?

CEO

Update CEO

CEO Approval Rating

- -/100

Cancer Therapeutics CRC is a biotechnology company that develops new drugs for cancer treatment.

See Cancer Therapeutics CRC company profile »

Stay up-to-date with the latest news on Cancer Therapeutics CRC